Hematology Conference - 2022 Highlights of ASH

This accredited continuing education activity “2022 Highlights of ASH”, is recorded from the live webinar held on 2/19/2022. 

If you participated in the live webinar titled - 2022 Highlights of ASH on 2/19/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 2/19/2022.  However, you may enroll in this activity to review the contents. 

The 2022 Highlights of ASH is a CME-accredited, in-person hematology conference featuring leading experts in the field. This conference allows professionals an opportunity to discuss current research and advances in the field of blood disorders and hematologic malignancies with colleagues and key opinion leaders. Expert faculty will place key abstract findings from the 63rd ASH Annual Meeting into clinical context and discuss how the results may change the current standard of care. The goals of this conference are to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for the patients. 

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, then you don't pay anything to register for this activity.

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting associated with this webcast and wish to register for this enduring material please contact us and we will register you for free.

Target Audience

  • Hematologists/Oncologists
  • Oncology and hematology residents/fellows
  • Oncology and hematology NPs/PAs
  • Oncology and hematology pharmacists
  • Oncology and hematology nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review data presented at the 63rd ASH Annual Meeting (2021) and discuss their application in clinical settings
  2. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for patients with blood disorders and hematologic malignancies
  3. Identify side effects, indications, and contra-indications of various therapies used to diagnose and treat blood disorders and hematologic malignancies, and explain how to effectively manage those side-effects
  4. Integrate emerging evidence into treatment paradigms for treatment of patients with blood disorders and hematologic malignancies
Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
03/03/2022
Course expires: 
03/03/2023
Cost:
$1.00

This educational activity features recorded videos from the live conference titled - 2022 Highlights of ASH held on 2/19/2022.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.


30 minutes: Myelodysplastic Syndromes - Paul Shami, MD

30 minutes: Myeloproliferative neoplasms including Chronic Myeloid Leukemia - Irum Khan, MD

32 minutes: Chronic Lymphocytic Leukemia - Parameswaran Venugopal, MD


Moderator: Binay Shah, MD, MPH

30 minutes: ITP/TTP, aHUS - George Rodgers III, MD, PhD

31 minutes: Clotting disorders - Doris V. Quon, MD, PhD

29 minutes: Bleeding disorders - Beth Warren, MD

13 minutes: Q&A


Moderator: Arvind Chaudhry, MD, PhD

34 minutes: Acquired Bone Marrow Failure Syndromes - Srinivas Tantravahi, MBBS, MRCP(UK)

40 minutes: Lymphoma - Grzegorz S. Nowakowski, MD  

11 minutes: Q&A


Moderator: Srinivas Tantravahi, MBBS, MRCP(UK)

40 minutes: Acute Leukemia - Jacob S. Appelbaum, MD, PhD

50 minutes: Myeloma - Shaji Kumar, MD

 

All relevant financial relationships of individuals in control of the content have been identified and mitigated. No members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity except for the following faculties: 

  • Dr. Grzegorz Nowakowski:  Commercial Interest(s): Celgene/BMS, Relationship: Consultant, Commercial Interest(s) MorphoSys, Relationship: Research support/Grant, Consultant, Commercial Interest(s): Roche/Genentech , Relationship: Consultant, Commercial Interest(s): Kite, Relationship: Consultant, Commercial Interest(s): TG Therapeutics, Relationship: Consultant, Commercial Interest(s): Ryvu, Relationship: Consultant, Commercial Interest(s): MEI, Relationship: Consultant
  • Dr. Irum Khan:  Commercial Interest(s): Bristol Myers Squibb, Relationship: Other, Please list if you selected other): Advisory Board
  • Dr. Paul Shami has a Commercial Interest(s): BMS, Relationship: Consultant, Commercial Interest(s): Bastion Biologic, Relationship: Speakers Bureau, Chief Medical Advisor, Chimerix, Relationship: Research support/Grant, Commercial Interest(s): JSK Therapeutics, Relationship: Other, Founder, Stock Holder, Chief Medical Officer, Commercial Interest(s): RJH Biosciences, Relationship: Consultant, Commercial Interest(s): Amgen, Relationship: Research support/Grant, Commercial Interest(s): Aptevo, Relationship: Research support/Grant, Commercial Interest(s): ONO, Relationship: Research support/Grant
  • Dr.Beth Warren has no relevant financial relationship to disclose. Off-label discussion: Dr. Warren will review ASH talk of emicizumab use in persons with acquired hemophilia A.

DISCUSSION OF OFF LABEL PRODUCTS

If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved. 

Speaker(s)

Jacob Appelbaum, MD/PhD

has no relevant financial relationships to disclose at this time.

Arvind Chaudhry, MD, PhD

has no relevant financial relationships to disclose at this time.

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Doris Quon, MD, PhD

has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Roche/Genentech;.
has a financial relationship (Professional Services) with NovoNordisk;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with uniQure;.
has a financial relationship (Professional Services) with Biomarin;.
has a financial relationship (Professional Services) with Octapharma;.

GEORGE RODGERS, MD, PhD

has a financial relationship (Professional Services) with Dova;.
has a financial relationship (Professional Services) with Argenx;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Paul Shami

has a financial relationship (Other) with JSK Therapeutics;.
has a financial relationship (Grant Or Contract) with ONO;.
has a financial relationship (Other) with Bastion Biologic;.
has a financial relationship (Grant Or Contract) with Aptevo;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with RJH Biosciences;.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Financial Support) with karyopharm therapeutics;.

Parameswaran Venugopal, MD

has a financial relationship (Professional Services) with AstraZeneca;.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT:

This activity has been supported with an independent medical education grant from Pharmacosmos. 

Important Information about Claiming CME for this activity:

If you participated in the live webinar titled - 2022 Highlights of ASH on 2/19/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 2/19/2022. However, you can still enroll in this activity and review the contents as needed.

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this enduring activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

Price

Cost:
$1.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.

If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you have started watching the recorded content.